Pdf Viewer

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Log Out

Therapy Areas

Products

Order Vaccines

Order Samples

Order

Materials

Request Samples

Hospital Products

Vaccines

Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Pfizer Dermatology Patient Access

Explore Content

Contact

Dosing

Efficacy & Safety

Efficacy &
Safety

Proven Efficacy

Safety & Tolerability

Novel Mechanism of Action

Samples

Resources

Materials

Videos

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-DUA-USA-0808

You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

INDICATIONS

Duavee® (conjugated estrogens/‌‌bazedoxifene) is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus:

Treatment of moderate to severe vasomotor symptoms associated with menopause
Prevention of postmenopausal osteoporosis

Limitations of Use: Duavee should be used for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.

When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.